# Oxford Drug Design

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxford-drug-design

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.oxforddrugdesign.com
- Total disclosed funding: $4.8M
- Latest round: Seed (Jan 24, 2022)
- Investors on record: 6

## About

Oxford Drug Design Limited is a biotechnology firm specializing in the innovative design and development of therapeutics using advanced techniques in artificial intelligence and tRNA synthetase enzyme targeting.Founded in 2017 in Oxford, UK, Oxford Drug Design Limited focuses on the development of therapeutics for significant health issues. The company has raised GBP 2.2 million in a Seed funding round on January 24, 2022, with investments from ACF Investors, Meltwind Advisory, o2h Ventures, and R42. The total amount raised to date is GBP 2.2 million, with a current company valuation of GBP 8.032 million. The CEO, Alan Roth, has a history in the biotech sector but specific prior ventures are not detailed.Oxford Drug Design specializes in designing and developing innovative therapeutics by leveraging advancements in science from Oxford. The focus is on creating targeted treatments for cancer and major diseases. Their products are marketed to pharmaceutical and biotechnology firms, as well as research institutions and healthcare providers, particularly in North America, Europe, and parts of Asia.In the most recent year, Oxford Drug Design reported a revenue of GBP 0, with an EBITDA of GBP -1,119,626.20 in 2018. The company's revenue generation primarily relies on B2B partnerships with pharmaceutical and biotechnology companies, engaging in strategic agreements that typically involve milestones and royalties linked to therapeutic advancements.Oxford Drug Design plans to utilize the GBP 2.2 million raised in the Seed funding round to enhance its computational design-led discovery focus. The company aims to expand its market presence, targeting new regions in North America and Europe, with specific timelines for product releases and market entries not detailed. Future product offerings are under development, although specific launch dates are not disclosed.

## Funding rounds

- Seed, Jan 24, 2022, $3M — ACF Investors, O2h Ventures, R42, Meltwind Advisory
- Series A, Mar 27, 2017, $1.9M — Longview Innovation, O2h Ventures, Busolantix Investment

## Investors

- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series A
- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Series A, Seed
- Busolantix Investment (https://capitalatlas.ai/funds/busolantix-investment) — Series A
- ACF Investors (https://capitalatlas.ai/funds/acf-investors) — Seed
- R42 (https://capitalatlas.ai/funds/r42) — Seed
- Meltwind Advisory (https://capitalatlas.ai/funds/meltwind-advisory) — Seed